sorafenib has been researched along with jnj 28312141 in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (jnj 28312141) | Trials (jnj 28312141) | Recent Studies (post-2010) (jnj 28312141) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 15 | 0 | 13 |
| Protein | Taxonomy | sorafenib (IC50) | jnj 28312141 (IC50) |
|---|---|---|---|
| High affinity nerve growth factor receptor | Homo sapiens (human) | 0.0825 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 1.994 | |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | 0.0007 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 4.8 | |
| Macrophage colony-stimulating factor 1 receptor | Mus musculus (house mouse) | 0.0026 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.023 | |
| Tyrosine-protein kinase receptor UFO | Homo sapiens (human) | 1.306 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0255 | |
| Glucagon receptor | Homo sapiens (human) | 0.8837 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Shi, K; Wang, J; Wang, Y; Zhang, J; Zhou, E | 1 |
1 review(s) available for sorafenib and jnj 28312141
| Article | Year |
|---|---|
Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities.
Topics: Apoptosis; Chemistry, Pharmaceutical; Drug Discovery; Humans; Receptor-Interacting Protein Serine-Threonine Kinases | 2022 |
1 other study(ies) available for sorafenib and jnj 28312141
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |